Full TitleA Phase 1/2 Open-Label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas
The purpose of this study is to find the highest dose of the investigational drug IGM-2323 that can be given safely in patients with non-Hodgkin lymphoma (NHL) that has come back or continued to grow despite prior treatment. IGM-2323 is a bispecific antibody that binds to two different proteins at the same time: one on the surface of cancer cells and one on the surface of immune cells called T cells. Researchers believe that IGM-2323 may enhance the ability of a patient’s own T cells to destroy cancer cells. IGM-2323 is given intravenously (by vein).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have NHL that came back or continued to grow after at least two prior regimens of therapy.
- Patients may not be candidates for stem cell transplantation.
- At least 4 weeks must pass since the completion of previous treatment and receipt of IGM-2323.
- Patients must be physically well enough that they are fully ambulatory, capable of all self-care, and capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Matthew Matasar at 212-639-8889.